Related Experiment Video

Updated: May 2, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.4K

[New molecular targeting drugs for metastatic colorectal cancer]

Yoshito Komatsu1, Kazuaki Harada1, Hiraku Fukushima1

  • 1Hokkaido University Hospital Cancer Center.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 7, 2014
PubMed

Insights

New colorectal cancer drugs target key molecular pathways. Regorafenib, aflibercept, and ramucirumab are discussed as novel treatments, with potential for combination therapies to improve outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Colorectal cancer remains a significant health challenge.
  • Targeted therapies offer new avenues for treatment.
  • Understanding molecular targets is crucial for drug development.

Purpose of the Study:

  • To outline novel molecularly targeted drugs for colorectal cancer.
  • To discuss the mechanisms of action for new therapeutic agents.
  • To introduce innovative combination chemotherapy regimens.

Main Methods:

  • Review of regorafenib as a multikinase inhibitor.
  • Description of aflibercept and ramucirumab as angiogenesis inhibitors.
  • Introduction of a novel combination chemotherapy regimen.

Main Results:

  • Regorafenib exhibits oral activity and targets multiple kinases.
  • Aflibercept and ramucirumab are effective anti-angiogenic agents.
  • Ramucirumab specifically inhibits vascular endothelial growth factor receptor 2 (VEGFR-2).

Conclusions:

  • Targeted therapies like regorafenib, aflibercept, and ramucirumab represent advancements in colorectal cancer treatment.
  • Inhibition of angiogenesis is a key strategy in managing metastatic colorectal cancer.
  • Combination chemotherapy regimens incorporating molecularly targeted drugs show promise for improved efficacy.

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

9.9K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164